Exosome RNA Exosome RNA Research & Industry News
MicroRNA-based treatment holds great promise for application as clinical antitumor therapy, but good carriers for delivery of the miRNA drug are lacking. Exosomes secreted by mesenchymal stem cells (MSCs) have proved to be safe, and exogenously modified exosomes may potentially represent an excellent drug delivery vehicle.
In this study, researchers at Xinjiang Medical University designed a delivery nano system using single-stranded variable fragment (scFv)-modified exosomes derived from human cord blood MSCs. Genetic engineering technology was used to obtain anti-Glypican 3 (GPC3) scFv-modified exosomes, which were then loaded with miR-26a mimics through electroporation.
Schematic illustration of the exosome-based drug delivery systems
(A) Design of the anti-GPC3 scFv-Lamp2b fusion constructs. (B) Schematic representation of the exosomes-based nanosystem preparation. (C) Uptake of anti-GPC3 scFv-modified exosomes by tumor cells. (D) Schematic illustration of the antitumor mechanisms of miR-26a mimics.
Results of electron microscopy and dynamic light scattering indicated that the diameter of the drug-carrying exosomes was about 160 nm. Furthermore, anti-GPC3 scFv-modified exosomes effectively delivered miR-26a to GPC3-positive hepatocellular carcinoma cells, thereby inhibiting cell proliferation and migration by regulating the expression of downstream target genes of miR-26a. The exosomes-based nano system displayed favorable anti-tumor effect in vivo with no obvious side effects.
This data provided a new perspective for the use of exosome delivery systems for miRNA-based antitumor therapy.
